Three of the medical device industry's biggest names have a lot riding on the cardiac rhythm management industry. Cardiac powerhouses Boston Scientific (NYSE:BSX) and St. Jude Medical (NYSE:STJ), as well as the market's largest pure medical device maker, Medtronic (NYSE:MDT), all draw a substantial portion of revenue from this hard-hit niche that's seen a slowdown in Europe and heightened rivalry in the industry pressure sales over the past few years. But can these top companies turn around sales losses?
Credit Medtronic for doing its best: This leading device maker has pushed for smaller pacemakers as it looks to inject growth in a sluggish business. Meanwhile, St. Jude and Boston Scientific have celebrated new approvals in this industry from U.S. regulators, but neither saw great performance from CRM revenue in their recent quarterly earnings reports.
Boston Scientific's stock in particular has thrived over the past year despite the ongoing CRM sluggishness, but can these top device picks keep charging higher? Find out in the video below, as Motley Fool contributor Dan Carroll takes you through how these companies rely so much on the CRM industry -- and whether you can count on a turnaround soon in this stumbling business.
Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
Dan Carroll has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.